Valneva SE.
VALN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. The company leverages its expertise and infrastructure to develop vaccines against diseases like Lyme disease, chikungunya, and other ...Show More
Better Health for All
10
Valneva's core business is the development and commercialization of prophylactic vaccines for infectious diseases, including the world's first chikungunya vaccine, IXCHIQ, and candidates for Lyme disease, Shigella, and Zika.
1
This focus on preventing diseases with unmet medical needs means 100% of its portfolio delivers substantial health benefits, with no revenue from harmful products. The company aims to make vaccines available at fair prices, collaborating with partners like Serum Institute of India and Instituto Butantan to ensure affordable access in low- and middle-income countries (LMICs) through technology transfers.
2
It actively works to expand access to vaccines in LMICs and underserved areas, including supporting infrastructure for vaccine delivery.
3
Valneva invested €74.143 million in R&D in 2024.
4
Its operations generate positive health externalities by reducing the need for antibiotics and by shifting to 100% renewable electricity at R&D and manufacturing sites, reducing CO2 emissions by 48% since 2019.
5
The company is committed to pandemic preparedness, focusing on vaccines suitable for outbreak responses in LMICs, and developed a COVID-19 vaccine.
6
It engages with healthcare professionals and participates in WHO's World Immunization Week to highlight the importance of vaccination.
7
Valneva has a Data Protection Policy, mandates regular employee training on privacy, and has implemented multiple layers of IT security.
8
The company supports technology transfers for its chikungunya vaccine to accelerate access in LMICs.
9
However, in February 2025, the CDC was investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among individuals 65 years and older.
10
In 2023, Valneva donated €33,460 to health-related charitable organizations, which is less than 0.02% of its €169.6 million 2024 revenue.
11
In 2024, the company had 44 recordable work-related accidents for its own workforce, with a Lost Time Injury Frequency Rate (LTIFR) of 5.89.
12
Pfizer discontinued approximately half of the participants in the Phase 3 trial of Valneva's Lyme disease vaccine candidate due to GCP violations at certain trial sites run by a third party.
13
Fair Money & Economic Opportunity
0
Valneva SE is a specialty vaccine company focused on the development and commercialization of vaccines. The ethical value 'Fair Money & Economic Opportunity' specifically evaluates how financial institutions democratize access to fair financial services, covering activities related to lending, insuring, moving, or storing money. As Valneva's core business is not in financial services, all KPIs under this value are deemed 'Not applicable' based on the rubric's definitions for a score of 0. The evidence provided, while indicating efforts to provide affordable vaccines and expand access to underserved populations and LMICs, pertains to healthcare products and not financial products or services.
1
Fair Pay & Worker Respect
0
In 2024, 71.6% of Valneva employees were covered by a collective bargaining agreement.
1
The company's Lost-Time Accident Frequency Rate (LTIFR) was 4.75 in 2023.
2
The Gender Pay Index was 3% in 2023, indicating a pay equity ratio of 0.97.
3
Employee engagement surveys resulted in an average rating of 3.7 out of 5 stars, with 65% of employees recommending working at Valneva.
4
The voluntary employee turnover rate was 23% in 2023.
5
Valneva reported no complaints or communications related to human rights issues in 2023 and found no indications of modern slavery, forced labor, or child labor within its operations or value chain in 2023 and 2024.
6
Fair Trade & Ethical Sourcing
0
No evidence available to assess Valneva SE on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Valneva has a formal whistleblower policy with a 24/7 helpline available in multiple languages, administered by an independent third party, and allows for anonymity.
1
Retaliation against whistle-blowers is prohibited.
2
The company also has a Global Anti-Bribery and Anti-Corruption Policy and adheres to California Health & Safety Code, Sections 119400-119402, including the OIG Compliance Guidance and PhRMA Code.
3
It provides regular employee training on these policies, including for external workforces and partners, and is a signatory of the UN Global Compact.
4
However, the policy's effectiveness metrics or customization for high-risk areas are not specified.
Kind to Animals
-40
Valneva successfully completed a pilot study in 2024, implementing a non-live animal-based sentinel monitoring program in R&D, which reduced the number of animals used in non-GxP studies to zero.
1
The company centralizes the registration and data collection of all external animal studies, and its animal laboratories are subject to regular, unannounced inspections by authorities.
2
Valneva's Animal Welfare Policy, effective January 2025, applies to all employees and partners, is guided by the 3Rs principles (Replacement, Reduction, and Refinement), and is publicly available.
3
External testing is only conducted in rare cases when required by regulatory obligations and is overseen by the Animal Welfare Body and Regulatory Affairs.
4
Valneva actively engages with public authorities to uphold animal welfare standards and collaborates with regulatory authorities.
5
By 2026, Valneva aims to assess 100% of key suppliers in EcoVadis and share its Business Partners Code of Conduct with 100% of suppliers.
6
The company uses horseshoe crab blood, a species listed as Vulnerable on the IUCN Red List, for pharmaceutical development and manufacturing, stating the blood is extracted without harming the crabs.
7
Valneva is considering alternative methods and has started feasibility studies for recombinant factor C (rFC) technology for two commercialized vaccines.
8
No War, No Weapons
0
No evidence available to assess Valneva SE on No War, No Weapons.
Planet-Friendly Business
-50
Valneva's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 59,310 tCO2e.
1
The company has a target to reduce Scope 1 and 2 CO2 emissions by 50% by 2030 from a 2022 baseline, but these targets are not yet SBTi-validated.
2
In 2024, the share of renewable sources in total energy consumption was 80%.
3
The water intensity ratio in 2024 was 315.7 m3 per million EUR net revenue.
4
In 2024, 65% of waste generated was recycled, and the company achieved zero-to-landfill at 100% of its manufacturing sites.
5
Valneva's EOHS Policy underscores the importance of life cycle analysis, but no specific percentage of product lines assessed is provided.
6
The company's CAPEX is 76% EU Taxonomy-eligible.
7
Valneva published its Business Partners Code of Conduct in 2024, requiring partners to measure and report their carbon footprint, and aims to assess 100% of key suppliers in EcoVadis by 2026.
8
However, no suppliers currently have SBTi-aligned targets.
9
The company has no stated net-zero target year.
10
Valneva intends to conduct a climate scenario analysis in 2025 and has partial TCFD mapping.
11
In 2024, 66% of commercial vaccines had plastic-free secondary packaging and blister-free packaging.
12
The company had zero major environmental compliance violations in 2024.
13
Valneva has started feasibility studies for recombinant factor C (rFC) technology for two vaccines, but has minimal pilot projects for biodiversity.
14
Respect for Cultures & Communities
50
Valneva has reported no cultural appropriation incidents
1
and commits to ethical sourcing and benefit sharing, including adherence to the Nagoya Protocol, which indicates a preventative framework.
2
The company provides formal grievance mechanisms, including a confidential 24/7 helpline, email, and website, which are available to all employees and non-employees across all operational sites.
3
Grievance mechanisms are communicated to employees in their local language,
4
and sustainability reports are available in English, French, and German.
5
All existing employees completed cultural sensitivity training when the Code of Conduct and Ethics was published in 2022 and again in 2023, with new employees also completing this training.
6
Safe & Smart Tech
0
Valneva demonstrates strong employee training, with 94% of employees successfully completing cybersecurity training in 2021.
1
The company has a global Data Protection Policy, a dedicated Data Protection Officer, and explicitly states compliance with GDPR and other applicable laws.
2
Valneva is a signatory of the UN Global Compact, committing to supporting fundamental principles in human rights.
3
For data minimization, the company collects only necessary data for pharmacovigilance, retaining it for 10 years after a product is off the market, and recruitment data for 7-12 months.
4
However, the company acknowledges that critical vulnerabilities are patched within 45-60 days on average, which is below industry best practices. User data control is basic, offering rights to access, rectify, erase, or transfer personal data, but lacks details on comprehensive privacy dashboards or frictionless processes.
5
Zero Waste & Sustainable Products
-30
Valneva achieved a waste diversion rate of 65.3% in 2024, with 100% of its manufacturing sites reaching zero-to-landfill in the same year.
1
For packaging, 99% of Valneva’s vaccines’ secondary packaging was recyclable in 2024, and 66% of commercial vaccines had plastic-free secondary packaging.
2
The company generated 18% less hazardous waste compared to 2023 and biological waste accounts for 34.5% of the Group’s total waste, subject to specific monitoring procedures.
3
Valneva conducts regular internal reviews and external audits to identify pollution risks.
4
The company has not reported any waste disposal violations in the past three years.
5
Valneva aims to reduce the proportion of non-recyclable and landfilled waste by 5% by 2025 compared to 2016, and the Livingston site targets reducing landfill waste from 19% to 2.5% in 2024.
6
By 2026, Valneva plans to define a Sustainable Procurement Policy with environmentally friendly criteria for suppliers and assess 100% of key suppliers in EcoVadis.
7